Teknova Announces New Board Member, Martha J. Demski
16 Agosto 2023 - 2:00PM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer
of critical reagents for the research, development, and
commercialization of novel therapies, vaccines, and molecular
diagnostics, today announced the appointment of Martha J. Demski to
its Board of Directors, bringing to the Board more than 35 years of
experience in corporate leadership and life sciences business and
financial strategies. She will replace Robert McNamara, who has
served on the Board since Teknova’s IPO in 2021 and has announced
his intention to step down to pursue other opportunities. Both Ms.
Demski’s appointment and Mr. McNamara’s resignation will be
effective on August 31, 2023.
“Martha has been a true partner and leader over
the course of her long-standing career in life sciences, and we’re
thrilled to welcome her to our Board at an important time in the
maturation of our company and as we continue to execute against our
established growth strategy,” said Stephen Gunstream, Teknova’s
President and Chief Executive Officer. “We’d also like to thank Bob
for his contributions to Teknova since our IPO. He consistently
provided expert guidance, especially in the areas of fiscal
management and corporate development. On behalf of the entire Board
of Directors, we wish him all the best in his future
endeavors.”
“I’m honored to join the Teknova team and am
excited to contribute my extensive experience and insights to their
vision of making solutions possible,” said Martha Demski. “Their
well-earned reputation in the life sciences reagents industry –
along with their strong execution on key growth initiatives over
the past few years – positions them well as they develop the
business to better support bioprocessing and gene therapy
companies.”
Ms. Demski was elected to serve on the Company’s
Board as an independent Director at its recent quarterly meeting on
August 8, 2023. In addition to her role as Director, she will serve
as chair of the Board’s Audit Committee and will join its
Compensation Committee as a member.
In addition to her over 35 years of experience
in life sciences companies, Ms. Demski currently serves as the Lead
Independent Director on the board of Chimerix, Inc. (CMRX), and as
an independent Director on the Equillium, Inc. (EQ) Board of
Directors. She was also recognized as Director of the Year in
Corporate Governance by the Corporate Directors Forum.
ABOUT
TEKNOVA Teknova makes
solutions possible. Since 1996, Teknova has been innovating the
manufacture of critical reagents for the life sciences industry to
accelerate the discovery and development of novel therapies that
will help people live longer, healthier lives. We offer fully
customizable solutions for every stage of the workflow, supporting
industry leaders in cell and gene therapy, molecular diagnostics,
and synthetic biology. Our fast turnaround of high-quality agar
plates, microbial culture media, buffers and reagents, and water
helps our customers scale seamlessly from RUO to GMP. Headquartered
in Hollister, California, with over 200,000 square feet of
state-of-the-art facilities, Teknova’s modular manufacturing
platform was designed by our team of scientists, engineers, and
quality control experts to efficiently produce the foundational
ingredients for the discovery and commercialization of novel
therapies.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Lug 2023 a Lug 2024